AstraZeneca's Imfinzi gets a lift in lung cancer from England's cost watchdogs

AstraZeneca’s Imfinzi is working to grab sales in a rival-free sector of the lung cancer market, and England’s cost watchdogs just gave it a boost. The National Institute for Health and Care Excellence said Thursday it would cover the treatment under its Cancer Drugs Fund.